

## First-line Treatment for Chronic Lymphocytic Leukaemia – The Time for Alemtuzumab?

a report by

**Claire Dearden**

Consultant Haematologist, and Head, Chronic Lymphocytic Leukaemia Unit, Royal Marsden Hospital and Institute of Cancer Research, London

DOI: 10.17925/EOH.2008.04.1.50

Chronic lymphocytic leukaemia (CLL) is a slow-progressing malignancy with remarkably variable prognosis. CLL has been considered to be a burden of the elderly, with the median age of diagnosis being 70 years. However, about one-third of patients are under 50 years of age at diagnosis. CLL is marked by clonal proliferation and accumulation of neoplastic B lymphocytes in the blood, bone marrow, lymph nodes and spleen. The clinical course of CLL is very heterogeneous: in some patients progression of the CLL is slow and death is either from an unrelated cause or due to infectious complications of the disease, while in others the disease may follow an aggressive clinical course, resulting in death shortly after diagnosis due to CLL or treatment-related complications.

### Clinical Staging

Two widely accepted clinical staging systems exist for CLL: the Rai<sup>1</sup> and Binet<sup>2</sup> systems. The Rai system is mostly used in the US, while the Binet system is more widely used in Europe. A modified Rai system has also been described, which reduces the number of prognostic groups from five to three. These staging systems categorise patients based on clinical features of CLL, and still form the basis of clinical decisions. The use of computed tomography (CT) scans and new biological markers are currently recommended only for evaluation in clinical trials, not in routine practice.<sup>3</sup>

### New Prognostic Factors

New prognostic factors have also been developed based on the genetic profile or immunophenotypic markers of the B lymphocytes (see *Table 1*). These include the mutational status of the immunoglobulin heavy-chain variable genes (IGVH),<sup>4-7</sup> cytogenetics,<sup>8,9</sup> CD38 expression<sup>9,10</sup> and levels of the signalling molecule zeta-chain-associated protein kinase 70 (ZAP-70)<sup>11-15</sup> and serum markers.<sup>16-18</sup> These new markers may allow for classification of patients into more refined risk categories than was

previously possible using the classic Rai and Binet staging systems. Some are more useful in the context of early stage A disease, when they can aid in prediction of risk of disease progression and need for therapy, while others – such as fluorescence *in situ* hybridisation (FISH) analysis for the presence of p53 deletion – have particular utility in predicting response to therapy. Since response to therapy is the most important prognostic factor for patient survival, predicting subsets of patients who will or will not respond to a given therapy can prevent unnecessary treatment toxicity and the emergence of clones resistant to treatment and enable selection of targeted therapies. The stratification of CLL patients into prognostic groups using these new markers is increasingly feasible, but before being used in routine clinical practice the methodology of the tests needs to be fully standardised and validated. Furthermore, these analyses need to be evaluated in prospective clinical trials. Nevertheless, they have the potential to have an impact on the routine management of CLL in the future.

### Treatment Decisions – The Current Standard of Care

Current treatment modalities for CLL include alkylating agents, purine analogues, monoclonal antibodies and stem cell transplantation. Current international guidelines,<sup>3</sup> based on studies from the French Co-operative Group on CLL<sup>19</sup> and the Cancer and Leukemia Group B,<sup>20</sup> and confirmed by a meta-analysis,<sup>21</sup> recommend that asymptomatic newly diagnosed patients with early-stage disease (Rai 0, Binet A) should be monitored without therapy until they have evidence of disease progression.<sup>3</sup> Although patients at Binet stage B usually benefit from treatment, some can also be monitored without therapy until there is evidence of progressive or symptomatic disease. Stage C patients require therapy.

In the past, the alkylating agent chlorambucil, with or without corticosteroids, was the most widely applied first-line treatment in patients with active disease, with clinical responses achieved in 40–77% of previously untreated patients.<sup>22,23</sup> Alkylator-based combination regimens, including those incorporating anthracyclins, have been compared with chlorambucil alone in prospective randomised studies.<sup>24</sup> The results indicated superior response rates (RRs) for patients treated with combination chemotherapy, but no benefit on survival.<sup>25</sup> A meta-analysis of 2,022 patients in 10 trials comparing combination therapy, six of which included anthracyclines, with chlorambucil with or without prednisolone showed an identical five-year survival of 48% in both groups.<sup>21</sup>

The introduction of purine analogues, specifically fludarabine monophosphate, was a major breakthrough that shifted CLL therapeutic strategy from palliation to substantial improvements in RRs and outcome. Fludarabine has been extensively studied in CLL and has



Claire Dearden is a Consultant Haematologist and Head of the Chronic Lymphocytic Leukaemia (CLL) Unit at the Royal Marsden Hospital and Institute of Cancer Research in London. Her research interests focus on mature B- and T-cell malignancies, including CLL, hairy cell leukaemia and T-cell leukaemias. She has been involved in clinical research studies using purine analogues, monoclonal antibodies and stem cell transplantation in a range of lymphoproliferative diseases. Dr Dearden has also worked in Africa and the Caribbean

performing further research on leukaemia epidemiology, Burkitt's lymphoma and adult T-cell leukaemia lymphoma. She is a member of numerous societies, including the British and American Societies of Haematology (BSH and ASH), is a member of the UK Medical Research Council Adult Leukaemia Working Party and the National Cancer Research Institute CLL Trials Group, is on the Executive Board of the UK CLL Forum and chairs the regional Tumour Working Group for Haematological Cancers. She has also authored or co-authored many journal articles, meeting abstracts and book chapters in the field of haematological malignancy. Dr Dearden trained in haematology at the Hammersmith, Royal Marsden and St George's Hospitals in London before joining Professor Daniel Catovsky's group to undertake research into lymphoid malignancy.

E: [claire.dearden@btinternet.com](mailto:claire.dearden@btinternet.com)

been shown to give better complete remission (CR) rates and progression-free survival (PFS) compared with the cyclophosphamide, doxorubicin and prednisone (CAP) regimen and with chlorambucil in randomised trials.<sup>26–29</sup> Although all patients eventually relapsed, the conclusion drawn from these studies was that fludarabine was one of the most active single agents in CLL and should form the building block of subsequent therapies. Since then, combinations of fludarabine and cyclophosphamide (FC) and, more recently, fludarabine, cyclophosphamide and mitoxantrone have been investigated. These agents gave high RRs in single-institution studies and showed higher CR rates and longer PFS than single-agent purine analogues.<sup>30,31</sup> In a small fraction of patients these combinations eradicated minimal residual disease (MRD). As with many malignancies, eradication of MRD translates into longer PFS and long-term survival.<sup>31</sup>

In the last two years, three large phase III studies comparing fludarabine alone versus combination FC therapy for CLL patients requiring their first treatment have reported the superior objective response rate (ORR), CR and PFS seen with the FC combination.<sup>32–34</sup> These trials included more than 1,000 patients overall, and in one study one-third of the patients were over 70 years of age and had similar RR and toxicity to those in the younger age group.<sup>34</sup> This has shifted the standard of care for CLL towards the use of FC combination therapy for younger patients (<65 years of age) and for fitter older patients without significant co-morbidities. Despite these encouraging results, patients with disease refractory to standard chemotherapy have a particularly poor prognosis, and currently there is no accepted standard treatment.

### Immunotherapy in Chronic Lymphocytic Leukaemia

Over the past two decades significant advances in the development of monoclonal antibodies have improved treatment results in a number of haemopoietic malignancies. In CLL, two antibodies have been studied: rituximab, a chimeric human–mouse anti-CD20, and alemtuzumab (campath-1H), a humanised anti-CD52 antibody.

Rituximab has proven efficacy for patients with B-cell lymphomas, especially when used in combination with chemotherapy. In CLL, when used as a single agent it is less effective, probably because of the lower expression of CD20 in this disease. However, in combination with purine analogues and alkylating therapy in the fludarabine and rituximab (FR) or fludarabine, cyclophosphamide and rituximab (FCR) regimens, results have been very promising.<sup>35,36</sup> As first-line therapy, FCR has induced remissions in >90% of patients, with CR seen in 70%.<sup>36</sup>

Alemtuzumab was the first of this class of drug to receive approval in the US and Europe for use in the treatment of patients with refractory CLL. More recently, it has been approved for the first-line treatment of patients with B-cell CLL (B-CLL) for whom fludarabine-based chemotherapy is not appropriate.

### Alemtuzumab in Chronic Lymphocytic Leukaemia

Alemtuzumab is a recombinant monoclonal antibody against CD52, a surface protein highly expressed on most normal and malignant B and T lymphocytes<sup>37</sup> but not on haemopoietic stem cells.<sup>38</sup> Once bound to CD52, alemtuzumab induces cell death by one or more of the following mechanisms: complement-dependent cellular cytotoxicity,

**Table 1: Prognostic Markers in Chronic Lymphocytic Leukaemia**

Characteristic	Favourable	Poor
Clinical stage	Binet A, Rai 0/I	Binet C, Rai III/IV
Gender	Female	Male
Lymphocyte morphology	Typical	'Atypical', increased pro-lymphocytes
Lymphocyte doubling time	>12 months	<12 months
Bone marrow biopsy	Nodular/interstitial	Diffuse
Serum markers (β2M, LDH, thymidine kinase, CD23)	Normal	Raised
Cytogenetic abnormalities	None, 13qdel (sole)	11q del, 17p del
IgVH genes	Mutated	Unmutated
CD38	<30%	>30%
ZAP 70	<20%	>20%

antibody-dependent cellular cytotoxicity and/or induction of apoptosis. In patients with relapsed or refractory CLL after fludarabine and alkylator therapy, alemtuzumab induced a 33% ORR, including some CRs, with additional clinical benefit seen in patients with stable disease.<sup>39</sup> A number of other small studies have confirmed the activity of alemtuzumab in patients with fludarabine-refractory CLL. In one of these studies a proportion of patients achieved eradication of MRD, and this was associated with improved survival.<sup>40</sup> Importantly, alemtuzumab is particularly active in those patients who have a *TP53* deletion detected by FISH and who typically are resistant to conventional fludarabine-based treatment.<sup>41–43</sup>

Another approach to the use of alemtuzumab is based on the concept that this monoclonal antibody may be effective at purging residual disease in patients who achieve a maximal response after fludarabine-based induction treatment. Results from a preliminary study in nine patients were encouraging, since all but one patient achieved CR and 33% became polymerase chain reaction (PCR)-negative for IG VH. Several studies using different schedules and doses have shown the feasibility of this approach, with improved responses in 50–60% of patients.<sup>44–47</sup> One study randomised patients to receive consolidation with alemtuzumab compared with observation and demonstrated improved PFS for the treatment arm.<sup>48–49</sup>

As yet, there is rather little published data on completed trials of alemtuzumab in combination regimens in either the refractory or first-line setting. Preliminary data suggest that fludarabine-based combinations are effective (ORR ~80% in relapsed CLL) and well tolerated; it remains to be seen how these compare with rituximab-based regimens.

### Alemtuzumab as First-line Therapy

Results from a phase II trial of alemtuzumab as first-line therapy for B-CLL showed an ORR of 81%. Moreover, seven patients achieved CRs and 26 partial responses.<sup>50</sup> In this study, alemtuzumab was administered subcutaneously for up to 18 weeks. The long-term follow-up report on these patients showed a median time to treatment failure of 28 months in the alemtuzumab group compared with 17 months in the matched historical controls who received various chemotherapy agents as first-line therapy.<sup>51</sup>

CAM307, an international, multicentre, open-label phase III trial, compared alemtuzumab with chlorambucil in previously untreated CLL

**Table 2: Response Rates for Front-line Therapy in Chronic Lymphocytic Leukaemia**

Agent	OR	CR	Reference
Chlorambucil	55%	2%	Hillmen, 2007 <sup>52*</sup>
Alemtuzumab (IV)	83%	24%	Hillmen, 2007 <sup>52*</sup>
Alemtuzumab (SC)	87%	19%	Lundin, 2002 <sup>50</sup>
Fludarabine	63%	20%	Rai, 2000 <sup>27</sup>
Rituximab	51%	4%	Hainsworth, 2003 <sup>54</sup>
Fludarabine + cyclophosphamide (FC)	94%	39%	Catovsky, 2007 <sup>34</sup>
FC + mitozantrone	91%	50%	Bosch, 2005 <sup>31</sup>
Fludarabine + rituximab	90%	47%	Byrd, 2003 <sup>35</sup>
FC + rituximab	95%	70%	Keating, 2005 <sup>36</sup>

\*CAM307 phase III prospective randomised trial comparing chlorambucil and alemtuzumab.

patients.<sup>52</sup> Patients were randomly assigned to alemtuzumab intravenously (IV) for 12 weeks (n=149) or chlorambucil (n=148). The ORR for the alemtuzumab group was significantly higher compared with the chlorambucil group (83 versus 55.4%). Furthermore, alemtuzumab was superior to chlorambucil as measured by PFS, with an overall median PFS of 14.6 months (95% confidence interval [CI] 12.–21.7 months) for patients in the alemtuzumab arm and 11.7 months (95% CI 9.9–13.2 months) for patients in the chlorambucil arm (stratified log-rank p=0.0001). Median follow-up was 24.5 months for alemtuzumab and 24.9 months for chlorambucil. The median time to alternative therapy was 23.3 months for alemtuzumab, with a median 11.7 weeks of therapy, and 14.7 months for chlorambucil, with a median 28.3 weeks of therapy. Thus, alemtuzumab treatment resulted in a treatment-free period of approximately 88 weeks compared with 36 weeks for chlorambucil. The very similar results seen in the study using subcutaneous alemtuzumab to those seen in CAM307 suggest that this route of administration may have the same efficacy as intravenous alemtuzumab and would be easier to manage in the outpatient setting. Also in agreement with the Lundin study,<sup>50</sup> cytomegalovirus (CMV) events were the most serious alemtuzumab-related adverse effects observed in the study. In patients with symptomatic CMV, ORR was 83% with 26% complete response, and in patients with asymptomatic CMV ORR was 92% with 29% complete response. Median PFS for all PCR-positive CMV patients was 14.6 months, the same as for the entire treatment arm, and all recovered with antiviral treatment. Other infections were similar in both arms of the study and there were no treatment-related deaths.

### The Place of Alemtuzumab in Current Treatment of Chronic Lymphocytic Leukaemia

Thus, the question arises: where do the CAM307 data and alemtuzumab fit in CLL treatment? Table 2 summarises the published response rates for those treatments (monotherapy and combinations) in current use for first-line treatment of CLL. These data seem to support the use of fludarabine-based combination therapy as first-line treatment in younger, fitter patients. For older patients or those with co-morbidities, who may be less able to tolerate such combination regimens, the treatment modality is less clear. Chlorambucil may still be an acceptable first-line therapy for this group. The recent UKLRF phase III study demonstrated that chlorambucil, fludarabine and FC are not as effective for patients with high-risk genomic features, including those with del(11q22.3) and del(17p13.1). This suggests that treatments using the p53 pathway for their activity are not very effective.<sup>34</sup> Therefore, new treatments that are independent of p53 should be considered for these patients. Alemtuzumab alone<sup>42,43</sup> or in combination with high-dose methylprednisolone<sup>53</sup> has been reported to overcome resistance to chemotherapy in a proportion of these patients. These encouraging data suggest that this monoclonal antibody might find its place as first-line therapy for those with p53-associated chemoresistance. The promising efficacy that alemtuzumab has displayed in the CAM307 trial and the better tolerability/toxicity profile seen in the first-line setting may also encourage its use in those patients who may be unable to receive conventional chemotherapeutic agents because of co-morbidities.

### Summary and Conclusion

The stratification of CLL patients into prognostic groups using new molecular markers has enabled the application of risk-tailored treatment strategies. Additionally, monoclonal antibodies have presented radical and improved treatments for CLL, and several trials continue to explore the full potential of these agents. In particular, the role of immunotherapy as first-line therapy in CLL needs to be further defined, together with addressing questions regarding the role of combination treatment and consolidation/maintenance strategies. The recently published CAM307 trial shows that the monoclonal antibody alemtuzumab is a highly effective agent suitable for first-line monotherapy of CLL. This may lead to the more confident use of alemtuzumab in specific subgroups of patients, such as those with *TP53* abnormalities, and to further exploration of combination regimens. The question of whether the beneficial effect obtained with monoclonal antibodies translates into a longer survival awaits answers. ■

- Rai KR, Sawitsky A, et al., *Blood*, 1975;46:219–34.
- Binet JL, Vaugier G, et al., *Am J Med*, 1977;63(5):683–8.
- Hallek M, Cheson BD, et al., *Blood*, 2008;111(12):5446–56.
- Hamblin TJ, Davis Z, et al., *Blood*, 1999;94:1848–54.
- Damle RN, Wasil T, et al., *Blood*, 1999;94:1840–47.
- Vasconcelos Y, Davi F, et al., *J Clin Oncol*, 2003;21:3928–32.
- Krober A, Sella T, et al., *Blood*, 2002;100:1410–16.
- Seiler T, Döhner H, et al., *Semin Oncology*, 2006;33:186–94.
- Dicker F, Schnitter S, et al., *Blood*, 2006;108:3152–60.
- Boonstra JG, et al., *Cytometry B Clin Cytom*, 2006;70:136–41.
- Rosenwald A, et al., *J Exp Med*, 2001;194:1639–47.
- Crespo M, et al., *N Engl J Med*, 2003;348(18):1764–75.
- Orchard JA, Ibbotson RE, et al., *Lancet*, 2004;363:105–11.
- Del Principe MI, Del Poeta G, et al., *Blood*, 2006;108:853–61.
- Kröber A, et al., *J Clin Oncol*, 2006;24(6):969–75.
- Knauf WJ, Ehlers B, Mohr B, et al., *Blood*, 1997;89:4241–2.
- Montillo M, et al., *Haematologica*, 2005;90:391–9.
- Pepper C, Ward R, Lin TT, et al., *Leukemia*, 2007;21:687–96.
- Dighiero G, et al., *N Engl J Med*, 1998;338:1506–14.
- Shustik C, Mick R, Silver R, et al., *Hematol Oncol*, 1988;6:7–12.
- CLL Trialists' Collaborative Group, *J Natl Cancer Inst*, 1999;91:861–8.
- Knosp WH, Loeb V, Hugulex CM, *Cancer*, 1974;33:555–62.
- Montserrat E, et al., *Cancer*, 1985;56:2369–75.
- Johnson S, Smith AG, et al., *Lancet*, 1996;347:1432–8.
- Raphael B, Andersen JW, et al., *J Clin Oncol*, 1991;9:770–76.
- French Cooperative Group on CLL, *Lancet*, 1996;347:1432–8.
- Rai KR, et al., *N Engl J Med*, 2000;343:1750–57.
- Johnson S, et al., *Lancet*, 1996;347:1432–8.
- Leporrier M, et al., *Blood*, 2001;98:2319–25.
- O'Brien SM, et al., *J Clin Oncol*, 2001;19:1414–20.
- Bosch F, Ferrer A, et al., *Br J Haematol*, 2002;119:976–84.
- Eichhorst BF, et al., *Blood*, 2006;107:885–91.
- Flinn IW, Neuberg DS, et al., *J Clin Oncol*, 2007;25:793–8.
- Catovsky D, Richards S, Matutes E, et al., UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group, *Lancet*, 2007;370(9583):230–39.
- Byrd JC, Rai K, Peterson BL, et al., *Blood*, 2005;105:49–53.
- Keating MJ, et al., *J Clin Oncol*, 2005;23:4079–88.
- Treumann A, et al., *J Biol Chem*, 1995;270:6088–99.
- Gilleece MH, Dexter TM, *Blood*, 1993;82:807–12.
- Keating MJ, Flinn I, Jain V, et al., *Blood*, 2002;99:3554–61.
- Moreton P, et al., *J Clin Oncol*, 2005;23:2971–9.
- Stilgenbauer S, Döhner H, *N Engl J Med*, 2002;347:452–3.
- Lozanski G, et al., *Blood*, 2004;103:3278–81.
- Osuji NC, et al., *Haematologica*, 2005;90:1435–6.
- Montillo M, Cafro AM, Tedeschi A, et al., *Haematologica*, 2002;87:695–700.
- Montillo M, et al., *J Clin Oncol*, 2006;24(15):2337–42.
- O'Brien SM, et al., *Cancer*, 2003;98:2657–63.
- Rai KR, Byrd JC, et al., *Blood*, 2003;102:676A, a2506.
- Wendtnr CM, et al., *Leukemia*, 2004;18:1093–1101.
- Schweighofer M, et al., *Blood*, 2006;108:14, a3.
- Lundin J, Kimby E, et al., *Blood*, 2002;100:768–73.
- Karlsson C, Norin S, et al., *Leukemia*, 2006;20:2204–7.
- Hillmen P, Skotnicki AB, et al., *J Clin Oncol*, 2007;25:5616–23.
- Pettitt AR, Matutes E, Oscier D, *Leukemia*, 2006;20:1441–5.
- Hainsworth JD, et al., *J Clin Oncol*, 2003;21:1746–51.



The European School of Haematology is a non-profit interdisciplinary institution for continuing education.

---

## UPCOMING CONFERENCES 2009

---

13-15 February, 2009 - Mandelieu, France

ESH Conference

### **HAEMATOLOGICAL ASPECTS OF AUTOIMMUNE DISEASES**

Chairs: **A. Newland, D. Provan, J. Semple, R. Stasi**

---

20-22 February, 2009 - Paris, France

ESH-EHA Annual Diagnostic Workup of

Hematological Malignancies:

### **FOCUS ON CHRONIC DISEASES**

Chairs: **B. Bain, R. Foà, G. Zini**

---

3-5 April, 2009 - Mandelieu, France

ESH-EHA Scientific Workshop on

### **LEUKAEMIC AND CANCER STEM CELLS:**

**Common and distinct features**

Chairs: **C. Chomienne, D. Bonnet, P. Valent, D. Louvard**

---

April, 2009 - Paris, France

ESH Conference

### **ANGIOGENESIS**

Chairs: **K. Alitalo, A. Bikfalvi, Ch. Betsholtz, A. Eichmann, A. Harris, C. Rüegg, G. Tobelem**

---

May, 2009 - United Kingdom

ESH-EBMT Training Course

### **HAEMOPOIETIC STEM CELL TRANSPLANTATION**

Chairs: **J. Apperley, E. Gluckman, E. Carreras, A. Gratwohl, T. Masszi**

---

June, 2009

ESH Conference

### **CLINICAL MANAGEMENT OF DISORDERS OF IRON METABOLISM**

Chairs: **Ph. Beris, M. Cappellini, J. Porter, A. Taher**

---

September, 2009 - Western Europe

ESH Eleventh International Conference

### **CHRONIC MYELOID LEUKAEMIA**

Chairs: **J. Goldman, J. Cortes**

---

October, 2009 - Mandelieu, France

ESH-EHA Scientific Workshop

### **INNOVATIVE THERAPIES FOR RED CELL AND IRON RELATED DISORDERS**

Coordinators: **Y. Beuzard, C. Camaschella**

---

Scholarships are available for most conferences

**For full information go to: [www.esh.org](http://www.esh.org)**

EUROPEAN SCHOOL OF HAEMATOLOGY

Centre Hayem, Hôpital Saint Louis - I, Avenue Claude Vellefaux

75475 Paris Cedex 10, France

Tel. (33) 6 33 30 84 22 or (33) 6 33 30 91 51 Fax. (33) 1 57 27 68 38

e.mails: [didi.jasmin@univ-paris-diderot.fr](mailto:didi.jasmin@univ-paris-diderot.fr) or [ghyslaine.lebougault@univ-paris-diderot.fr](mailto:ghyslaine.lebougault@univ-paris-diderot.fr) or

[marie-france.simon@univ-paris-diderot.fr](mailto:marie-france.simon@univ-paris-diderot.fr) or [nancy.hamilton@univ-paris-diderot.fr](mailto:nancy.hamilton@univ-paris-diderot.fr) or

[celine.caudroit@univ-paris-diderot.fr](mailto:celine.caudroit@univ-paris-diderot.fr) or [caroline.lamy@univ-paris-diderot.fr](mailto:caroline.lamy@univ-paris-diderot.fr) or

[sylvain.lepen@univ-paris-diderot.fr](mailto:sylvain.lepen@univ-paris-diderot.fr)